|Bid||188.24 x 200|
|Ask||189.30 x 300|
|Day's Range||187.23 - 190.25|
|52 Week Range||152.16 - 201.23|
|PE Ratio (TTM)||69.98|
|Forward Dividend & Yield||5.28 (2.78%)|
|1y Target Est||N/A|
Leonard Schleifer, Regeneron CEO, speaks with CNBC’s Meg Tirrell about the company’s new cholesterol drug data and the issues around prescription drug pricing.
A cholesterol drug made by Regeneron and Sanofi was shown to reduce the risk of cardiac events like heart attack and stroke, reports CNBC's Meg Tirrell with the latest results.
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
Assessing Amgen Inc’s (NASDAQ:AMGN) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense check to buildRead More...
In 4Q17, Merck’s (MRK) Emend generated revenues of $143 million, which reflected a ~1% decline on a YoY (year-over-year) basis but a 4% rise on a QoQ (quarter-over-quarter) basis. In 4Q17, in the US and in international markets, Emend reported revenues of $85 million and $58 million, respectively, compared with $90 million and $53 million in 4Q16, which reflected a ~6% decline and an 8% rise, respectively, YoY. In fiscal 2017, Emend generated revenues of $556 million, compared with $549 million in 2016, which reflected a ~1% rise YoY.
Esperion popped Monday after a study from Regeneron and Sanofi validated the long-term benefits of lowering LDL cholesterol.
Drugmakers tried just about every move under the sun to nurture sales of its products -- pharmacy coupons for patients, exclusive deals with insurers, even selling a medicine’s patent to a Native American ...
A dramatic gambit to bring down drug prices did the job. The problem? It's awful for the patients caught in the middle.
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, tumbled alongside the broader market in February. In fact, IBB’s February loss surpassed those ...
The makers of an expensive cholesterol-lowering drug plan to offer discounts of up to 69% in exchange for insurers and pharmacy-benefit managers expanding their coverage of the medicine to more patients....
The FDA issued mostly positive decisions on the approval front last week. Theratechnologies Inc. (OTC: THERF ) shares gained more than 35 percent following the FDA's approval of Trogarzo injection, its ...
Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent, if insurers agree to lessen onerous access barriers for high-risk patients. Since the approvals in 2015 of Praluent and a similar rival biotech drug from Amgen Inc, insurers and pharmacy benefit managers have been rejecting some 70 percent of prescriptions written, severely holding back sales and frustrating doctors and at-risk heart patients.
New data in hand, Regeneron and Sanofi plan to offer insurers new rebates and discounts. Can they end the Mexican standoff that has prevented even the neediest patients from getting a promising drug?